...
首页> 外文期刊>Behavioural Brain Research: An International Journal >Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.
【24h】

Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.

机译:焦虑症的调节通过急性阻断和小鼠中CB(1)大麻素受体的基因缺失以及前脑中的生物胺变化。

获取原文
获取原文并翻译 | 示例
           

摘要

The CB(1) cannabinoid receptor has been implicated in the control of fear and anxiety. We investigated the effects of genetic and pharmacological blockade of the CB(1) cannabinoid receptor on the behaviour of CD1 mice using three different ethological models of fear and anxiety (elevated T-maze and plus-maze and open field test of emotionality). Furthermore, we measured tissue levels of noradrenalin (NA), dopamine (DA), serotonin (5-HT) and their metabolites in several forebrain regions, i.e. prefrontal cortex, hippocampus, septum, dorsal and ventral striatum to examine the relationship between CB(1) receptor manipulation and monoaminergic neurotransmission. The major findings can be summarized as follows: the CB(1) receptor antagonist SR141617A (rimonabant) modulated anxiety in a dose-dependent manner. At a dose of 3 mg/kg i.p., the compound consistently increased anxiety parameters in all of the three different anxiety tests applied, while a lower dosage of 1mg/kg had no such effect. The neurochemical evaluation of the mice administered 3mg/kg SR141617A revealed increases in the concentrations of DOPAC and 5-HIAA in the dorsal striatum, elevated DA levels in the hippocampus and reduced dopamine turnover in the septum. Furthermore, these animals had a higher HVA/DA turnover in the frontal cortex. CB(1) receptor knockout mice as well as mice treated with the selective CB(1) receptor antagonist AM251 (3 mg/kg; i.p.) did not display any significant alterations in anxiety-related behaviour as measured with the elevated plus-maze and open field test of emotionality, respectively. Our findings support the general idea of a SR141617A-sensitive receptive site that is different from the 'classical' CB(1) receptor and that has a pivotal role in the regulation of different psychological functions. However, with regard to its functional significance in terms of anxiety our findings suggest that under physiological conditions this receptive site seems to be involved in the control of anxiolysis rather thananxiogenesis as suggested previously.
机译:CB(1)大麻素受体已牵涉到恐惧和焦虑的控制。我们使用三种不同的恐惧和焦虑行为学模型(升高的T迷宫和正迷宫以及开放性情绪测试)研究了CB(1)大麻素受体的遗传和药理学阻断作用对CD1小鼠行为的影响。此外,我们测量了前额叶皮层,海马,间隔,背侧和腹侧纹状体的几个前脑区域的去甲肾上腺素(NA),多巴胺(DA),5-羟色胺(5-HT)及其代谢产物的组织水平,以检查CB( 1)受体操纵和单胺能神经传递。主要发现可归纳如下:CB(1)受体拮抗剂SR141617A(利莫那班)以剂量依赖性方式调节焦虑。腹膜内注射剂量为3 mg / kg时,在所有三种不同的焦虑测试中,该化合物均不断增加焦虑参数,而较低的1mg / kg剂量则无此作用。给予3mg / kg SR141617A的小鼠的神经化学评估显示,背侧纹状体中DOPAC和5-HIAA的浓度增加,海马中的DA水平升高,并且隔中的多巴胺转换降低。此外,这些动物的额叶皮层具有较高的HVA / DA周转率。 CB(1)受体基因敲除小鼠以及用选择性CB(1)受体拮抗剂AM251(3 mg / kg; ip)处理的小鼠在焦虑相关行为方面没有表现出任何显着改变,如升高的迷宫和迷宫所测。分别进行开放性情绪测试。我们的发现支持SR141617A敏感受体位点的一般想法,该位点不同于“经典” CB(1)受体,并且在调节不同的心理功能中具有关键作用。但是,就其在焦虑方面的功能意义而言,我们的发现表明,在生理条件下,该接受部位似乎参与了抗焦虑作用的控制,而不是先前提出的焦虑发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号